Category: Latest Research
-
TGen, NAU study examines body’s antibody response to COVID-19 vaccine
Could the SARS-CoV-2 vaccine reawaken previous antibody responses and point the way to a universal coronavirus vaccine? A new analysis of the antibody response to a COVID-19 vaccine suggests the immune system’s past history with other coronaviruses, including those behind the common cold, shapes the patients response, according to a study published today in Cell Reports.
-
Study involving TGen, City of Hope uses DNA in the bloodstream to guide treatment for cancer patients
TGen and City of Hope investigators Kamel Lahouel and Cristian Tomasetti are working on study to help guide cancer treatment.
-
TGen study allows late-stage cancer patients to use their health data to guide care
A unique study pairing researchers from the Translational Genomics Research Institute (TGen), part of City of Hope, with one cancer patient is now underway to help answer that question. Rick Stanton, a former engineer and advanced prostate cancer patient, is at the center of TGen’s Patient Engagements, Operational Practices, and Laboratory Environment Standardization (PEOPLES) protocol.
-
TGen begins testing animals in captivity and nature for COVID-19
Working with state and federal wildlife agencies and private and public zoos across Arizona, the Translational Genomics Research Institute (TGen), part of City of Hope, is testing wild animals in captivity and in nature for SARS-CoV-2, the pathogen that causes COVID-19 in humans.
-
UArizona College of Medicine – Phoenix’s Ayman Fanous contributes to largest worldwide study of Schizophrenia
In a paper published April 8 in Nature, specific genes were identified that could play important roles in the psychiatric disorder. In the largest genetic study of schizophrenia, researchers including Ayman Fanous, MD, analyzed DNA from 76,755 people with schizophrenia and 243,649 without it to better understand the genes and biological processes underpinning the condition.
-
Catheter-based cardioneural ablation safe, effective for recurrent fainting, according to UArizona COM-P report
e by as much as 80% for patients with symptoms despite medical intervention and behavioral modification who did not desire permanent pacing.
-
TGen-led study suggest a drug combination that might prove effective for 1 in 3 glioblastoma patients
Based on the findings of a new study led by the Translational Genomics Research Institute (TGen), part of City of Hope, a coast-to-coast clinical trial is planned that, if successful, could lead […]
-
7th Annual ABRC-Flinn Research Conference highlights wide range of translational research
Translational research in pancreatic and chronic lung diseases, opioid receptors, West Nile Virus, Rocky Mountain Spotted Fever transmission, autism in older adults and insulin-dependent diabetes were among the topics discussed at the 7th ABRC-Flinn Research Conference.
-
TGen, HonorHealth and Irish biomedical team initiate promising ‘Nieto’ clinical trial against pancreatic cancer
association with HonorHealth Research and Innovation Institute and Systems Biology Ireland (SBI), have begun a clinical trial, testing the combination of two drugs against advanced pancreatic cancer, one of the most deadly and difficult-to-treat malignancies.